Literature DB >> 2505007

Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl.

J Knoll1, J Dallo, T T Yen.   

Abstract

The influence of longterm deprenyl treatment on the sexual performance and lifespan of male rats was studied. One hundred and thirty two rats were treated from the end of their 2nd year of life either with saline (1 ml/kg, s.c.) (n = 66) or with deprenyl (0.25 mg/kg, s.c.) (n = 66) three times a week until death. Whereas none of the two-year-old saline-treated rats displayed full scale sexual activity, this appeared in 64 out of 66 rats on deprenyl. The longest living rat in the saline-treated group lived 164 weeks. The lifespan of the group was 147.05 +/- 0.56 weeks. The shortest living animal in the (-)deprenyl-treated group lived 171 weeks and the longest living rat died during the 226th week of its life. The lifespan was 191.91 +/- 2.31 weeks. This is the first instance that a well aimed medication prolonged lifespan of members of a species beyond their maximum age of death (182 weeks in the rat). A close relation between sexual activity and lifespan was detected.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2505007     DOI: 10.1016/0024-3205(89)90103-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

1.  Pergolide can induce soluble superoxide dismutase in rat striata.

Authors:  A Clow; T Hussain; V Glover; M Sandler; M Walker; D Dexter
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 2.  The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).

Authors:  I Miklya
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

3.  Supplementation of deprenyl attenuates age associated alterations in rat cerebellum.

Authors:  Manju V Subramanian; T J James
Journal:  Mol Biol Rep       Date:  2010-03-07       Impact factor: 2.316

Review 4.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

5.  (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

Authors:  J Knoll; F Yoneda; B Knoll; H Ohde; I Miklya
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 6.  The hypothalamus in MPTP-induced parkinsonism.

Authors:  R Sandyk; R P Iacono; S R Kay
Journal:  Ital J Neurol Sci       Date:  1990-08

7.  Prolongation of life in an experimental model of aging in Drosophila melanogaster.

Authors:  R G Jordens; M D Berry; C Gillott; A A Boulton
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

Review 8.  The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog.

Authors:  N W Milgram; G O Ivy; E Head; M P Murphy; P H Wu; W W Ruehl; P H Yu; D A Durden; B A Davis; I A Paterson
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

Review 9.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  (-)-Deprenyl can induce soluble superoxide dismutase in rat striata.

Authors:  A Clow; T Hussain; V Glover; M Sandler; D T Dexter; M Walker
Journal:  J Neural Transm Gen Sect       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.